Wendy Lee, MD, sat down with Ophthalmology Times to discuss a symposium she participated in at Eyecon 2024 focusing on ...

Thyroid eye disease (TED) is an autoimmune condition that causes swelling and damage to the tissues around your eyes. There are two phases of TED: an active phase and an inactive phase. The active ...

THEY may be the window to your soul, but it turns out your eyes can also be a window to your overall health. While your ...

Among patients with autoimmune hyperthyroidism, those who use cannabis were 1.9 times more likely to develop exophthalmos ...

All the time leading up to this and almost all the time since, I've only had one short "active" period of thyroid eye disease (TED). My only noticeable symptom was double vision, but it went away ...

Acelyrin's Lonigutamab offers a competitive edge with subcutaneous administration, higher potency, and lower adverse events.

Amgen yesterday revealed that Tepezza (teprotumumab [genetical recombination]) has been approved for the treatment of active ...

(RTTNews) - Amgen (AMGN) said that Japan's Ministry of Health, Labour and Welfare approved TEPEZZA (Teprotumumab) for the treatment of active or high clinical activity score (CAS) Thyroid Eye Disease ...

Optometry cochairs Kelly K. Nichols, OD, MPH, PhD, FAAO, and A. Paul Chous, OD, MA, FAAO, highlight the conference’s focus on ...

Viridian Therapeutics shares rose ahead of market open on Tuesday after reporting positive results from the phase 3 trial for its thyroid eye disease treatment. Shares traded nearly 14% higher at ...

Amgen (NASDAQ:AMGN) today announced TEPEZZA® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the treatment of active or high ...